NSCLC: primary tumor size--radiation dose-related accelerated, twice daily radiotherapy by target splitting, preceded by 2 cycles of chemotherapy--first results of a prospective study.
Wurstbauer
Karl
K
University Clinic of Radiation Oncology, Salzburger Landeskliniken und Paracelsus Medizinische Privatuniversität, Salzburg, Austria. k.wurstbauer@salk.at
Deutschmann
Heinz
H
Kopp
Peter
P
Kranzinger
Manfred
M
Merz
Florian
F
Nairz
Olaf
O
Studnicka
Michael
M
Sedlmayer
Felix
F
D000206:Actuarial Analysis; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008168:Lung / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011446:Prospective Studies; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D020266:Radiotherapy, Conformal; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors
D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents; D016190:Carboplatin; D002945:Cisplatin